BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 37364772)

  • 1. Bumetanide as a Model NDSRI Substrate: N-nitrosobumetanide Impurity Formation and its Inhibition in Bumetanide Tablets.
    Shakleya D; Asmelash B; Alayoubi A; Abrigo N; Mohammad A; Wang J; Zhang J; Yang J; Marzan TA; Li D; Shaklah M; Alsharif FM; Desai S; Faustino PJ; Ashraf M; O'Connor T; Vera M; Raw A; Sayeed VA; Keire D
    J Pharm Sci; 2023 Dec; 112(12):3075-3087. PubMed ID: 37364772
    [TBL] [Abstract][Full Text] [Related]  

  • 2. N-nitrosamine Mitigation with Nitrite Scavengers in Oral Pharmaceutical Drug Products.
    Bayne AV; Misic Z; Stemmler RT; Wittner M; Frerichs M; Bird JK; Besheer A
    J Pharm Sci; 2023 Jul; 112(7):1794-1800. PubMed ID: 37023856
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of N-Nitrosamine Formation in Drug Products: A Model Study.
    Nanda KK; Tignor S; Clancy J; Marota MJ; Allain LR; D'Addio SM
    J Pharm Sci; 2021 Dec; 110(12):3773-3775. PubMed ID: 34400183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Caffeic and ferulic acid as blockers of nitrosamine formation.
    Kuenzig W; Chau J; Norkus E; Holowaschenko H; Newmark H; Mergens W; Conney AH
    Carcinogenesis; 1984 Mar; 5(3):309-13. PubMed ID: 6368031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NDMA Formation Due to Active Ingredient Degradation and Nitrite Traces in Drug Product.
    Golob N; Peterlin S; Grahek R; Roškar R
    J Pharm Sci; 2023 May; 112(5):1277-1286. PubMed ID: 36925105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temperature-Dependent Formation of N-Nitrosodimethylamine during the Storage of Ranitidine Reagent Powders and Tablets.
    Abe Y; Yamamoto E; Yoshida H; Usui A; Tomita N; Kanno H; Masada S; Yokoo H; Tsuji G; Uchiyama N; Hakamatsuka T; Demizu Y; Izutsu KI; Goda Y; Okuda H
    Chem Pharm Bull (Tokyo); 2020 Oct; 68(10):1008-1012. PubMed ID: 32779580
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Nitrite Excipient Database: A Useful Tool to Support N-Nitrosamine Risk Assessments for Drug Products.
    Boetzel R; Schlingemann J; Hickert S; Korn C; Kocks G; Luck B; Blom G; Harrison M; François M; Allain L; Wu Y; Bousraf Y
    J Pharm Sci; 2023 Jun; 112(6):1615-1624. PubMed ID: 35500671
    [TBL] [Abstract][Full Text] [Related]  

  • 8. N-Nitrosodimethylamine formation in metformin hydrochloride sustained-release tablets: Effects of metformin and hypromellose used in drug product formulation.
    Hao G; Hu R; Wang X; Gao P; Wang L; Jiang M; Xin L; Tan G; Zhao Y; Sun F; Chu D; Lv J; You J; Huang F; Song X
    J Pharm Biomed Anal; 2023 Jan; 222():115066. PubMed ID: 36191442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. N-Nitrosamine Formation in Pharmaceutical Solid Drug Products: Experimental Observations.
    Moser J; Ashworth IW; Harris L; Hillier MC; Nanda KK; Scrivens G
    J Pharm Sci; 2023 May; 112(5):1255-1267. PubMed ID: 36736774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modeling the Impact of Excipients Selection on Nitrosamine Formation towards Risk Mitigation.
    Berardi A; Jaspers M; Dickhoff BHJ
    Pharmaceutics; 2023 Jul; 15(8):. PubMed ID: 37631229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Determining recommended acceptable intake limits for N-nitrosamine impurities in pharmaceuticals: Development and application of the Carcinogenic Potency Categorization Approach (CPCA).
    Kruhlak NL; Schmidt M; Froetschl R; Graber S; Haas B; Horne I; Horne S; King ST; Koval IA; Kumaran G; Langenkamp A; McGovern TJ; Peryea T; Sanh A; Siqueira Ferreira A; van Aerts L; Vespa A; Whomsley R
    Regul Toxicol Pharmacol; 2024 Jun; 150():105640. PubMed ID: 38754805
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the protective effect of ascorbic acid on nitrite- and nitrosamine-induced cytotoxicity and genotoxicity in human hepatoma line.
    Erkekoglu P; Baydar T
    Toxicol Mech Methods; 2010 Feb; 20(2):45-52. PubMed ID: 20100056
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Investigating the root cause of N-nitrosodimethylamine formation in metformin pharmaceutical products.
    Nasr NEH; Metwaly MG; Ahmed EO; Fares AR; ElMeshad AN
    Expert Opin Drug Saf; 2021 Jul; 20(7):855-862. PubMed ID: 33849366
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of nitrosamine contaminants in drug samples: Has the crisis been overcome?
    Schmidtsdorff S; Neumann J; Schmidt AH; Parr MK
    Arch Pharm (Weinheim); 2023 Feb; 356(2):e2200484. PubMed ID: 36461687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nitrosated Active Pharmaceutical Ingredients - Lessons Learned?
    Holzgrabe U
    J Pharm Sci; 2023 May; 112(5):1210-1215. PubMed ID: 36720391
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Landscape of Potential Small and Drug Substance Related Nitrosamines in Pharmaceuticals.
    Schlingemann J; Burns MJ; Ponting DJ; Martins Avila C; Romero NE; Jaywant MA; Smith GF; Ashworth IW; Simon S; Saal C; Wilk A
    J Pharm Sci; 2023 May; 112(5):1287-1304. PubMed ID: 36402198
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modified NAP test: A simple and Responsive Nitrosating Methodology for Risk Evaluation of NDSRIs.
    Sharma N; Patel R; Bothara T; Jain S; Shah RP
    J Pharm Sci; 2023 May; 112(5):1333-1340. PubMed ID: 36871894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NITROSOGENESIS, ANTIDEPRESSANTS AND THE SERTRALIN INDUCED NEVUS ASSOCIATED CUTANEOUS MELANOMA: THE NDMA/ NNK (NDSRIS) CONTAMINATION AS MOST POTENT MELANOMA INDUCTORS: ALEA IACTA EST.
    Tchernev G
    Georgian Med News; 2023 Sep; (342):47-53. PubMed ID: 37991956
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Studies on nitrosamine formation by the interaction between drugs and nitrite. I. Measurement of the amount of nitrosamine formed in rat and guinea pig stomachs.
    Kawanishi T; Ohno Y; Takahashi A; Ishiwata H; Tanimura A; Kasuya Y; Omori Y
    J Toxicol Sci; 1981 Nov; 6(4):261-70. PubMed ID: 7338958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Avoiding N-nitrosodimethylamine formation in metformin pharmaceuticals by limiting dimethylamine and nitrite.
    Schlingemann J; Boucley C; Hickert S; Bourasseau L; Walker M; Celdran C; Chemarin T; Pegues C; Fritzsche M; Keitel J; Goettsche A; Seegel M; Leicht S; Guessregen B; Reifenberg P; Wetzel S; Müller T; Schooren F; Schuster T; Liebhold M; Kirsch A; Krueger P; Saal C; Mouton B; Masanes S
    Int J Pharm; 2022 May; 620():121740. PubMed ID: 35421534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.